Microglial Activation Role In ALS (MARIA)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

EARLY_PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuroinflammation, characterized in particular by microglia activation, is an essential component of Amyotrophic Lateral Sclerosis (ALS) pathogenesis. Translocator Protein (TSPO) is recognized as a specific and sensitive biomarker of neuroinflammation, reflecting disease activity. An experimental radiopharmaceutical specific of TSPO expression, namely \[18F\]DPA714, allow to quantify this microglial activation using Positon Emission Tomography (PET) imaging.

The purpose of this study is to longitudinally correlate the spatial distribution of neuroinflammation with the pro- or anti-inflammatory state of activated microglia cells in ALS, in order to evaluate neurotoxic or neuroprotective microglia activity, by complementary approaches in 20 ALS patients:

* in vitro: measuring concentrations of several pro- and anti-inflammatory cytokines secreted by microglial cells in the cerebrospinal fluid (CSF).
* in vivo: \[18F\]DPA714 PET imaging. These assays will be performed in the framework of the clinical follow-up of ALS patients, at the diagnosis of ALS disease and 6 months latter.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging of Intracerebral Inflammation in MS

NCT02305264

Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive

COMPLETED NA

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

NCT01428505

Multiple Sclerosis

TERMINATED PHASE2

The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis

NCT06290453

Multiple Sclerosis

NOT_YET_RECRUITING

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)

NCT06280742

Multiple Sclerosis

NOT_YET_RECRUITING NA

Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis

NCT04220814

Multiple Sclerosis, Relapsing-Remitting

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyotrophic Lateral Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

amyotrophic lateral sclerosis (ALS)

\[18F\]DPA-714 PET

Group Type EXPERIMENTAL

[18F]DPA-714 PET

Intervention Type DRUG

\[18F\]DPA-714 Positron Emission Tomography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]DPA-714 PET

\[18F\]DPA-714 Positron Emission Tomography

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

[18F]DPA-714

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent
* Age ≥ 18 years old
* Patient with probable or definite sporadic Amyotrophic Lateral Sclerosis (ALS) form according to the modified criteria of El Escorial
* Treated with riluzole 2 weeks
* Evolution less than 18 months
* Mini-Mental State Examination (MMS) score ≥ 26 and Frontal Assessment Battery (FAB) (normal)
* Affiliated to a social security system

Exclusion Criteria

* Another unbalanced progressive pathology
* Vascular diseases (hypertension, diabetes, smoking, dyslipidemia) unbalanced
* Forced vital capacity \<75%
* Weight loss\> 10% of the weight before disease
* Status "low affinity binder" or "mixed affinity binder", the TSPO respect to the \[18 F\] DPA-714, which can interfere with the process of neuroinflammation: drugs with anti-inflammatory drugs (NSAIDs, corticosteroids, azathioprine, anti-tumor necrosis factor (TNF), antibiotics)
* Benzodiazepine in the week before the PET scan \[18F\] DPA-714 given the potential consequences for TSPO receivers
* Contraindications to MRI in patients with:

1. Metallic foreign body eye.
2. Any implanted electronic medical irremovably (pacemaker, neurostimulator, cochlear implants ...)
3. Metal heart valve,
4. Vascular clips formerly located on cranial aneurysm.
* Treatment in the month before the PET scan \[18F\] DPA-714 antagonist N-methyl-D-aspartate (NMDA) (memantine)
* Pregnant women, lactating women, and women in age for procreation and without reliable contraception or without history of hysterectomy
* ◦Person under guardianship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No